Please provide the following information relating to NSCLC patients treated by your Trust in the 3 months, December 2017 to February 2018 inclusive.
If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.
1. Total number treated Stage IIIB/IV NSCLC Patients
If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:
2. Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies.
Total number treated Stage IIIB/IV NSCLC Patients
If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:
Docetaxel (mono or combination therapy)
Atezolizumab (Tecentriq)
Nivolumab (Opdivo)
Pembrolizumab (Keytruda)
3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:
